Edition:
India

INSYS Therapeutics Inc (INSY.OQ)

INSY.OQ on NASDAQ Stock Exchange Global Market

7.10USD
16 Nov 2018
Change (% chg)

$-0.13 (-1.80%)
Prev Close
$7.23
Open
$7.19
Day's High
$7.26
Day's Low
$7.01
Volume
74,394
Avg. Vol
146,231
52-wk High
$14.00
52-wk Low
$5.04

Latest Key Developments (Source: Significant Developments)

Insys Therapeutics Signs Agreement With Lunatus To Commercialize Subsys In The Middle East
Monday, 1 Oct 2018 

Oct 1 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS SIGNS DEFINITIVE LICENSE AGREEMENT WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST.INSYS THERAPEUTICS INC - INSYS WILL SUPPLY SUBSYS TO LUNATUS, AND LUNATUS WILL OBTAIN REGULATORY APPROVALS AND COMMERCIALIZE SUBSYS IN TERRITORY.INSYS THERAPEUTICS - SIGNED LICENSE AGREEMENT WITH LUNATUS FOR COMMERCIALIZATION OF SUBSYS (FENTANYL SUBLINGUAL SPRAY) IN 8 COUNTRIES IN MIDDLE EAST.  Full Article

FDA Grants Insys Therapeutics ‘Fast Track’ Designation For Epinephrine Nasal Spray As Investigational Treatment For Anaphylaxis
Thursday, 30 Aug 2018 

Aug 30 (Reuters) - INSYS Therapeutics Inc ::FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR EPINEPHRINE NASAL SPRAY AS INVESTIGATIONAL TREATMENT FOR ANAPHYLAXIS.  Full Article

Insys Therapeutics Q2 Adj Shr Loss $0.33
Thursday, 9 Aug 2018 

Aug 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS REPORTS SECOND QUARTER 2018 RESULTS.Q2 NET REVENUE $23.5 MILLION VERSUS $42.6 MILLION.Q2 LOSS PER SHARE $0.37.Q2 ADJUSTED LOSS PER SHARE $0.33.BELIEVE WE REMAIN ON TRACK TO SUBMIT AN NDA FOR NALOXONE NASAL SPRAY BY END OF 2018.Q2 REVENUE VIEW $25.9 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.  Full Article

Insys Therapeutics Q2 Loss Per Share $0.37
Thursday, 9 Aug 2018 

INSYS Therapeutics Inc ::INSYS THERAPEUTICS REPORTS SECOND QUARTER 2018 RESULTS.Q2 LOSS PER SHARE $0.37.Q2 REVENUE $38 MILLION VERSUS $58.2 MILLION.Q2 REVENUE VIEW $25.9 MILLION -- THOMSON REUTERS I/B/E/S.Q2 EARNINGS PER SHARE VIEW $-0.16 -- THOMSON REUTERS I/B/E/S.Q2 ADJUSTED LOSS PER SHARE $0.33.BELIEVE WE REMAIN ON TRACK TO SUBMIT AN NDA FOR NALOXONE NASAL SPRAY BY END OF 2018.  Full Article

Insys Therapeutics Reaches Agreement In Principle To Settle DOJ Investigation
Wednesday, 8 Aug 2018 

Aug 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS REACHES AGREEMENT IN PRINCIPLE TO SETTLE DEPARTMENT OF JUSTICE INVESTIGATION.INSYS THERAPEUTICS INC - INSYS ALSO EXPECTS THAT A FINAL SETTLEMENT WOULD INCLUDE OTHER MATERIAL NON-FINANCIAL TERMS.INSYS - AGREEMENT IN PRINCIPLE TO SETTLE CIVIL AND CRIMINAL INVESTIGATION INTO INAPPROPRIATE SALES, COMMERCIAL PRACTICES BY SOME FORMER CO EMPLOYEES.INSYS - CONSISTENT WITH PREVIOUS PUBLIC STATEMENTS & DISCLOSURES, TERMS OF AGREEMENT IN PRINCIPLE CALL FOR CO TO PAY $150 MILLION OVER 5 YRS.  Full Article

Insys Therapeutics Receives Complete Response Letter From FDA For Buprenorphine NDA
Friday, 27 Jul 2018 

INSYS Therapeutics Inc ::INSYS THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR BUPRENORPHINE NDA.INSYS THERAPEUTICS - CRL INDICATES THAT SOME BUPRENORPHINE NDA DATA SUGGESTED POTENTIAL SAFETY CONCERNS.  Full Article

Insys Therapeutics Responds To Unsealing Of Previously Filed Qui Tam Complaints
Tuesday, 15 May 2018 

May 15 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS RESPONDS TO UNSEALING OF PREVIOUSLY FILED QUI TAM COMPLAINTS AND RECAPS TRANSFORMATION EFFORTS.INSYS THERAPEUTICS - ONGOING DIALOGUE WITH DOJ HAS NOT RESULTED IN INFORMATION THAT WOULD CAUSE CO TO REVISE ESTIMATE OF MINIMUM LIABILITY EXPOSURE.INSYS THERAPEUTICS SAYS CONTINUES TO HAVE ONGOING DIALOGUE WITH U.S. DOJ REGARDING INVESTIGATION THAT IN DEC 2013 WAS COMMENCED BY DOJ'S CIVIL DIVISION.  Full Article

Insys Therapeutics Announces Exclusive License Partnership To Commercialize Subsys In Middle East
Wednesday, 9 May 2018 

May 8 (Reuters) - INSYS Therapeutics Inc ::INSYS THERAPEUTICS ANNOUNCES EXCLUSIVE LICENSE PARTNERSHIP WITH LUNATUS TO COMMERCIALIZE SUBSYS® (FENTANYL SUBLINGUAL SPRAY) IN THE MIDDLE EAST.INSYS - CO'S RESPONSIBILITIES WILL INCLUDE SUPPLYING SUBSYS TO LUNATUS, WHOSE RESPONSIBILITIES WILL INCLUDE OBTAINING APPROVALS TO COMMERCIALIZE SUBSYS.INSYS - LUNATUS WILL BE EXCLUSIVE LICENSEE FOR SUBSYS IN BAHRAIN, JORDAN, KUWAIT, LEBANON, OMAN, QATAR, SAUDI ARABIA AND UNITED ARAB EMIRATES.  Full Article

Insys' Treatment For Prader-Willi Syndrome Gets ‘Fast Track’ Designation
Tuesday, 26 Dec 2017 

Dec 26 (Reuters) - Insys Therapeutics Inc ::FDA GRANTS INSYS THERAPEUTICS ‘FAST TRACK’ DESIGNATION FOR CANNABIDIOL (CBD) ORAL SOLUTION AS INVESTIGATIONAL TREATMENT FOR PRADER-WILLI SYNDROME.INSYS THERAPEUTICS - PLAN TO START CLINICAL DEVELOPMENT PROGRAM FOR CANNABIDIOL ORAL SOLUTION IN LATE Q1 OF 2018.  Full Article

Insys Therapeutics Inc - ‍Study Is Expected To Be Completed In Late 2018 For Of Cbd Oral Solution-A​
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - Insys Therapeutics Inc ::INSYS THERAPEUTICS INITIATES PHASE 2 CLINICAL TRIAL OF CANNABIDIOL (CBD) ORAL SOLUTION FOR TREATMENT OF REFRACTORY CHILDHOOD ABSENCE EPILEPSY IN PEDIATRIC PATIENTS.INSYS THERAPEUTICS INC - ‍STUDY IS EXPECTED TO BE COMPLETED IN LATE 2018 FOR OF CBD ORAL SOLUTION-A​.  Full Article

Photo

Maryland charges Insys with engaging in deceptive opioid scheme

Maryland on Thursday charged Insys Therapeutics Inc with deceptively marketing a powerful opioid pain killer so that it was prescribed inappropriately beyond its intended use with cancer patients.